The statins, HMG CoA-reductase inhibitors which lower serum cholesterol, exhibit myriad clinical benefits including enhanced vascular integrity. One potential mechanism underlying increased endothelial cell (EC) barrier function is inhibition of geranylgeranylation, a covalent modification enabling translocation of the small GTPases Rho and Rac to the cell membrane. While RhoA inhibition attenuates actin stress fiber formation and promotes EC barrier function, Rac1 inhibition at the cell membrane potentially prevents activation of NADPH oxidase and subsequent generation of superoxides known to induce barrier disruption. We examined the relative regulatory effects of simvastatin on RhoA, Rac1 and NADPH oxidase activities in the context of human pulmonary artery EC barrier protection. Confluent EC treated with simvastatin demonstrated significantly decreased thrombin-induced FITC-dextran permeability, a reflection of vascular integrity, which was linked temporally to simvastatin-mediated actin cytoskeletal rearrangement. Compared to Rho inhibition alone (Y27632), simvastatin afforded additional protection against thrombin-mediated barrier dysfunction and attenuated LPS-induced EC permeability and superoxide generation. Statin-mediated inhibition of both Rac translocation to the cell membrane and superoxide production were attenuated by geranylgeranyl pyrophosphate indicating that these effects are due to geranylgeranylation inhibition.
Introduction
The statins, a class of HMG-CoA reductase inhibitors, are widely used for their ability to significantly lower serum cholesterol levels and their beneficial effects on morbidity and mortality associated with coronary artery disease. Recently, however, there has been intense interest in the precise mechanism of action of this class of drugs as the clinical effects of statins are now recognized to extend well beyond their lipid-lowering properties (2, 4) . In this regard, we have previously reported that endothelial cell (EC) barrier protection is conferred by simvastatin following prolonged treatment (16 their geranylgeranylation and subsequent translocation to the cell membrane (16, 34) . This localization of small GTPases to the cell membrane in turn favors GTP binding and thus GTPase activation. The relevance of these effects to EC barrier function is significant as RhoA activation is an important mediator of acto-myosin contraction, actin stress fiber formation, and the resultant increased intracellular tensile forces that directly determine EC barrier integrity (7). Additionally, the inhibition of RhoA by statins leads to the upregulation of endothelial nitric oxide synthase (eNOS) and, subsequently, increased nitric oxide (NO) bioavailability which promotes vasorelaxation and inhibits platelet activation (25).
The role of Rac in EC barrier function is less well characterized. We have previously another 10 min at room temperature. After removal of the OPTI-MEM, the final mixture was mixed with EGM-2 medium (Clonetics) and added to cells. After overnight incubation, the transfection medium was aspirated and replaced with complete medium and incubated for another 48-72 h.
Measurement of superoxide production: DHE, a cellular membranepermeable fluorophore hydroethidine, was used to measure EC superoxide production. Briefly, EC were serum starved overnight and then loaded with 10 µM DHE in basal EGM-2 medium (Clonetics) for 30 min. After washing with PBS, the cells were then stimulated with lipopolysaccharide (LPS) for 1 h in basal medium without supplements. An aliquot (100 µl) of medium was used for fluorescent density assay on an Aminco-Bowman series 2 spectrofluorometer (Thermo Electron Corporation, Brookfield, WI) with excitation and emission set at 470 and 610 nm, respectively.
Membrane isolation: EC were grown to confluence, washed with ice-cold PBS and harvested with hypotonic buffer (5 mM Tris-HCl, pH 7.6, 2mM EDTA containing proteinease inhibitor, 1 mM NaVO 4 and 20 mM NaF). Detached cells were homogenized twice for 30 s each. After centrifugation at 400 g for 10 min at 4°C, the supernatant was then centrifuged at 12000 g for 30 min. The pellet was washed three times with HEPES-Tyrode's buffer containing proteinase inhibitors.
To dissolve the membrane protein, the same buffer containing 1% (v/v) Nonidet P-40, 4 mM CHAPS, or 10 mM CHAPS, 0.5% (w/v) desoxycholate was added to the pellet for 60 min at 4°C and the centrifuged at 14,000 g for 30 min at 4°C .
The supernatant was collected for protein assays. In vitro vascular permeability assay: A commercially available kit (Chemicon, Temecula, CA) was used to measure EC monolayer permeability to high molecular weight proteins utilizing 2,000 kDa FITC-dextran based upon the transwell model we previously described (13 Results are expressed as the mean ± standard error.
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Results
Time course of EC barrier protection and cytoskeletal rearrangement produced by simvastatin. We previously reported a delayed effect of simvastatin on EC barrier protection as measured by TER with a requirement for 16 h pretreatment to produce significant TER changes, a time frame corresponding with increased Rac1 activation (Rac-GTP). Accordingly, we have postulated that EC barrier enhancement by simvastatin largely involves activation of Rac. We sought to further characterize the time-dependent effects of simvastatin using a FITC-dextran transwell assay to measure EC monolayer permeability (15) . EC grown to confluence on transwell filters were stimulated with thrombin (1 U/mL, 1 h) resulting in significant increases in passage of FITC-dextran across the monolayer that was significantly attenuated by simvastatin pretreatment (5 µM) as brief as 6 hrs with a ~60% reduction in permeability compared to control ( Figure 1A ). Of note, a significant effect was not appreciable after 2 h of simvastatin treatment prior to thrombin stimulation and in separate experiments we were unable to detect an effect with either simultaneous simvastatin treatment or simvastatin administered at any time after thrombin (data not shown). However, we observed a significant effect of simvastatin on the EC actin cytoskeleton consistent with evidence of early EC barrier protection by simvastatin ( Figure 1B Importantly, simvastatin did not affect a significant change in total Rac as measured by the combined densitometry of membrane and cell fractions from these experiments or in whole cell lysates in separate experiments (data not shown).
Although we have previously reported modest upregulation of Rac1 gene expression (~1.3 fold increase) by simvastatin (3), our findings now suggest that this does not correspond to significant transcriptional upregulation of Rac1. Finally, similar to the effects of simvastatin (5 µM, 16 h), siRNA specific for Rac1 also effected a signficant attenuation of LPS-induced (1 µM, 30 min) superoxide generation ( Figure 5C ).
EC barrier protection by simvastatin is not solely attributable to Rac1
inhibition. We again employed siRNA specific for Rac1 to assess the contribution of Rac1 inhibition on agonist-induced EC barrier permeability relative to the effects of simvastatin pretreatment. Using EC transfected with scrambled siRNA as controls, siRac1 effected a ~20% decrease in thrombin-induced (1 U/ml, 1 h) EC permeability as measured by FITC-dextran transwell permeability ( Figure 6 ).
However, a more pronounced effect was observed in EC that were both transfected with siRac1 and pretreated with simvastatin (5 µM, 16 h). This effect was not significantly different from simvastatin pretreatment alone prior to thrombin stimulation. These data suggest that the inhibition of Rac1 and NADPH oxidase activity, similar to RhoA inhibition, contributes to but is not solely responsible for EC barrier protection by simvastatin.
EC barrier protection by simvastatin is not mediated by inhibition of Cdc42.
As the Rho GTPase known as Cdc42 is dependent on geranylgeranylation and may also regulated EC permeability, we used siRNA to determine its functional role in Consistent with early simvastatin effects on Rho GTPase activity, we now observed evidence of similar cytoskeletal changes in simvastatin-treated EC within 2 h that were more pronounced at 16 h. These changes correspond to the time-dependent effects of simvastatin on EC barrier protection as measured by transmonolayer FITC-dextran permeability. Relying solely on measurements of transendothelial electrical resistance, we were previously unable to detect evidence of EC barrier protection by simvastatin with pretreatment durations of less than 16 h and had hypothesized this was likely due to delayed Rac1 activation (21). Although these measurements are thought to be fairly sensitive they are at least somewhat limited by virtue of being an indirect measurement of permeability. Indeed, our data now draw into question the sensitivity of our earlier findings and require a revision of our original hypothesis as evidence of early barrier protection (dextran flux) by simvastatin clearly indicates a barrier-regulatory mechanism independent of late Rac1 activation. However, the additional benefit of simvastatin above the inhibitory effects on RhoA suggests a Rho-independent protective mechanism. In this regard, our data are consistent with the contribution of membrane-associated Rac1 inhibition with downstream consequences for NADPH oxidase activity.
Activation of NADPH oxidase has been implicated as an important mediator of injury in various models of murine ALI (12, 35). Separately, simvastatin has been shown to inhibit phorbol ester-induced superoxide production in whole blood from patients with sepsis (10). Moreover, in a model of diabetes-induced vascular injury mediated by oxidative stress, the selective inhibition of Rac1 has been found to be protective (38). Our data indicate that simvastatin produces a marked decrease in LPS-induced superoxide production consistent with the inhibition of NADPH oxidase activity.
These effects were associated with reduced translocation to the cell membrane of the NADPH oxidase regulatory subunits, Rac1 and p47 phox via inhibition of geranylgeranylation and an attenuation of LPS-induced EC permeability. We observed a modest effect on thrombin-induced EC permeability using siRac1
suggesting that Rac1 inhibition alone does not represent the primary mechanism of simvastatin-mediated EC barrier protection. The increased cytosolic Rac1-GTP induced by statins potentially represents a significant mediator of EC barrier protection in which case the use of siRac1 would not be expected to replicate barrier protection comparable to statins. Notably, we used two different agonists in our current studies, thrombin and LPS. While these agonists evoke different signaling pathways culminating in EC barrier disruption they do share some common features including the activation of both RhoA and Rac1 (17, 39, 43) as well as the induction of EC superoxide generation (18, 27, 33). Importantly, our data suggest that the observed effects of simvastatin on EC barrier regulation are related to these events rather than to other potentially non-specific effects. Finally, our conclusion that the protective effects of simvastatin in vivo are not solely due to Rac1 inhibition and the inhibition of superoxide generation via NADPH oxidase is indirectly supported by the lack of any clinical evidence of a therapeutic role for the use of antioxidants in ALI (1).
Aside from EC actin cytoskeletal effects, statin inhibition of RhoA also effects eNOS upregulation which leads to increased NO production (25). In turn, NO serves as a potent vasodilator as well as an inhibitor of platelet activation. Additionally, NO rapidly reacts with superoxide to produce peroxynitirite (ONOO -), a powerful oxidant, the activity of which has been associated with severity of injury in human ALI (24).
Undoubtedly, these effects contribute to the well described beneficial effects of statins on vascular function in a number of disparate clinical settings (15, 26, 36 ).
However, we have previously confirmed that the attenuation of agonist-induced EC permeability by simvastatin is uneffected by concomitant treatment with L-NAME, an eNOS inhibitor (21). Consequently, we have hypothesized that cytoskeletal rearrangement alone accounts for the contribution of EC barrier protection conferred by RhoA inhibition in our experiments and are most relevant to the protective effects of simvastatin in our murine model of ALI.
The limitations of our current study include the reliance on the use pharmacologic inhibitors in several experiments from which our conclusions are drawn. We recognize the potential non-specific effects associated with these inhibitors and acknowledge that these experiments, by themselves, are not definitive. While the results from these experiments and the conclusions drawn are strengthened by complementary studies in which we employed siRNA, a more specific technique, the results of our study do not preclude the possibility of alternate mechanisms contributing to EC barrier protection by simvastatin.
In summary, our results confirm a dual effect of simvastatin on Rac1 with Rac1 
